207 related articles for article (PubMed ID: 19939875)
1. Harms associated with psychoactive substances: findings of the UK National Drug Survey.
Morgan CJ; Muetzelfeldt L; Muetzelfeldt M; Nutt DJ; Curran HV
J Psychopharmacol; 2010 Feb; 24(2):147-53. PubMed ID: 19939875
[TBL] [Abstract][Full Text] [Related]
2. Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.
Morgan CJ; Noronha LA; Muetzelfeldt M; Feilding A; Curran HV
J Psychopharmacol; 2013 Jun; 27(6):497-506. PubMed ID: 23438502
[TBL] [Abstract][Full Text] [Related]
3. Experienced drug users assess the relative harms and benefits of drugs: a web-based survey.
Carhart-Harris RL; Nutt DJ
J Psychoactive Drugs; 2013; 45(4):322-8. PubMed ID: 24377171
[TBL] [Abstract][Full Text] [Related]
4. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
Rychert M; Wilkins C; Parker K; Witten K
Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
[TBL] [Abstract][Full Text] [Related]
5. Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.
Bonnet U; Specka M; Kanti AK; Scherbaum N
Front Psychiatry; 2022; 13():1041762. PubMed ID: 36465301
[TBL] [Abstract][Full Text] [Related]
6. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.
Parrott AC; Milani RM; Parmar R; Turner JD
Psychopharmacology (Berl); 2001 Dec; 159(1):77-82. PubMed ID: 11797073
[TBL] [Abstract][Full Text] [Related]
7. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
Gillet C; Polard E; Mauduit N; Allain H
Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
[TBL] [Abstract][Full Text] [Related]
8. Novel psychoactive substances: What educators need to know.
Patterson ZR; Young MM; Vaccarino FJ
Clin Pharmacol Ther; 2017 Feb; 101(2):173-175. PubMed ID: 27756105
[TBL] [Abstract][Full Text] [Related]
9. Does perception of drug-related harm change with age? A cross-sectional online survey of young and older people.
Cheeta S; Halil A; Kenny M; Sheehan E; Zamyadi R; Williams AL; Webb L
BMJ Open; 2018 Nov; 8(11):e021109. PubMed ID: 30401725
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with psychoactive substance use among a sample of prison inmates in Ilesa, Nigeria.
Amdzaranda PA; Fatoye FO; Oyebanji AO; Ogunro AS; Fatoye GK
Niger Postgrad Med J; 2009 Jun; 16(2):109-14. PubMed ID: 19606190
[TBL] [Abstract][Full Text] [Related]
11. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
[TBL] [Abstract][Full Text] [Related]
12. Emerging psychoactive substance use among regular ecstasy users in Australia.
Bruno R; Matthews AJ; Dunn M; Alati R; McIlwraith F; Hickey S; Burns L; Sindicich N
Drug Alcohol Depend; 2012 Jul; 124(1-2):19-25. PubMed ID: 22209387
[TBL] [Abstract][Full Text] [Related]
13. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
[TBL] [Abstract][Full Text] [Related]
14. [Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts].
Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck G; Wodarz N; Scherbaum N
Fortschr Neurol Psychiatr; 2022 Jan; 90(1-02):19-29. PubMed ID: 33634461
[TBL] [Abstract][Full Text] [Related]
15. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
[TBL] [Abstract][Full Text] [Related]
16. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
Soussan C; Andersson M; Kjellgren A
Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
[TBL] [Abstract][Full Text] [Related]
17. Physical harm due to chronic substance use.
van Amsterdam J; Pennings E; Brunt T; van den Brink W
Regul Toxicol Pharmacol; 2013 Jun; 66(1):83-7. PubMed ID: 23542091
[TBL] [Abstract][Full Text] [Related]
18. The Internet and psychoactive substance use among innovative drug users.
Boyer EW; Shannon M; Hibberd PL
Pediatrics; 2005 Feb; 115(2):302-5. PubMed ID: 15687436
[TBL] [Abstract][Full Text] [Related]
19. European rating of drug harms.
van Amsterdam J; Nutt D; Phillips L; van den Brink W
J Psychopharmacol; 2015 Jun; 29(6):655-60. PubMed ID: 25922421
[TBL] [Abstract][Full Text] [Related]
20. Perceived risk associated with tobacco, alcohol and cannabis use among people with and without psychotic disorders.
Thornton LK; Baker AL; Johnson MP; Lewin T
Addict Behav; 2013 Jun; 38(6):2246-51. PubMed ID: 23507458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
